CompletedPhase 3NCT01705145

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vertex Pharmaceuticals Incorporated
Principal Investigator
Margaret Rosenfeld, MD
Seattle Children's Hospital
Intervention
Ivacaftor(drug)
Enrollment
35 target
Eligibility
2-5 years · All sexes
Timeline
2013 – 2014

Study locations (20)

Collaborators

Cystic Fibrosis Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01705145 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis →

← Back to all trials